These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 2687812)

  • 1. Recent advances in the management of biotherapy-related side effects: flu-like syndrome.
    Haeuber D
    Oncol Nurs Forum; 1989; 16(6 Suppl):35-41. PubMed ID: 2687812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physical symptoms of combination biotherapy: a quality-of-life issue.
    Brophy LR; Sharp EJ
    Oncol Nurs Forum; 1991; 18(1 Suppl):25-30. PubMed ID: 1997974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis.
    Girouard N; Théorêt G
    Can J Neurosci Nurs; 2008; 30(4):18-25. PubMed ID: 19146204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nursing care of patients receiving activated lymphocytes.
    Brogley JL; Sharp EJ
    Oncol Nurs Forum; 1990; 17(2):187-93. PubMed ID: 2315182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biotherapy: recent advances and nursing implications.
    Mayer DK
    Nurs Clin North Am; 1990 Jun; 25(2):291-308. PubMed ID: 2186383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of recombinant interleukin 1alpha and etoposide in patients with relapsed osteosarcoma.
    Worth LL; Jaffe N; Benjamin RS; Papadopoulos NE; Patel S; Raymond AK; Jia SF; Rodriguez C; Gano J; Gianan MA; Kleinerman ES
    Clin Cancer Res; 1997 Oct; 3(10):1721-9. PubMed ID: 9815556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
    Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
    J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of biotherapy and nursing considerations.
    Coleman C
    J Intraven Nurs; 1998; 21(6):367-73. PubMed ID: 10392103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerance of sequential or simultaneous administration of IL-3 and G-CSF in improving peripheral blood stem cells harvesting following multi-agent chemotherapy: a pilot study.
    D'Hondt V; Guillaume T; Humblet Y; Doyen C; Chatelain B; Feyens AM; Staquet P; Osselaer JC; Müll B; Symann M
    Bone Marrow Transplant; 1994 Mar; 13(3):261-4. PubMed ID: 7515299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antineoplastic drug and headache].
    Hamada J
    Brain Nerve; 2008 Feb; 60(2):149-55. PubMed ID: 18306663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological response modifiers used in cancer biotherapy.
    Kuroki M; Miyamoto S; Morisaki T; Yotsumoto F; Shirasu N; Taniguchi Y; Soma G
    Anticancer Res; 2012 Jun; 32(6):2229-33. PubMed ID: 22641656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases.
    Paolozzi F; Zamkoff K; Doyle M; Konrad M; Bradley EC; Rudolph A; Newman N; Gullo J; Scalzo A; Poiesz B
    J Biol Response Mod; 1989 Apr; 8(2):122-39. PubMed ID: 2786553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerance of interferon-alpha therapy in children with chronic hepatitis B.
    Liberek A; Łuczak G; Korzon M; Szlagatys-Sidorkiewicz A; Bako W; Góra-Gebka M; Rytlewska M; Sikorska-Wiśniewska G
    J Paediatr Child Health; 2004; 40(5-6):265-9. PubMed ID: 15151579
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion.
    Honkanen H; Piaggio G; Hertzen H; Bártfai G; Erdenetungalag R; Gemzell-Danielsson K; Gopalan S; Horga M; Jerve F; Mittal S; Thi Nhu Ngoc N; Peregoudov A; Prasad RN; Pretnar-Darovec A; Shah RS; Song S; Tang OS; Wu SC;
    BJOG; 2004 Jul; 111(7):715-25. PubMed ID: 15198763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A perspective on the clinical effectiveness and tolerance of interferon-alpha.
    Borden EC; Parkinson D
    Semin Oncol; 1998 Feb; 25(1 Suppl 1):3-8. PubMed ID: 9482534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological response modifiers in cancer therapy.
    Gupta S; Kanodia AK
    Natl Med J India; 2002; 15(4):202-7. PubMed ID: 12296474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Methods for evaluating biological response modifiers].
    Harousseau JL
    Bull Cancer; 1998 Dec; 85(12):993-6. PubMed ID: 9917552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy by biological response modifiers].
    Urushizaki I
    Rinsho Ketsueki; 1989 Aug; 30(8):1230-2. PubMed ID: 2689681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of systemic versus inhaled recombinant IL-2 administration for the treatment of metastatic renal cell carcinoma.
    Huland E; Heinzer H; Huland H
    Folia Biol (Praha); 2000; 46(6):241-50. PubMed ID: 11140857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.